What You Should Know:
- More than 1500 Stanford faculty and alumni announced the launch of StartX Med COVID-19 Task Force featuring 70+ StartX Med Innovators with medical breakthroughs for the prevention, diagnostics, and treatment of coronavirus mobilize efforts to fast-track public health needs during the pandemic.
- The StartX Med COVID-19 Task Force will collaborate on outreach to government agencies, regulatory bodies and healthcare systems in the interest of public health for
Read More
Top 60 Health IT/Digital Health Mergers & Acquisitions in 2019
- From Google's acquisition of Fitbit to Philips acquisition of Carestream Health's health IT business, here is a look at some of the biggest health IT/digital health mergers & acquisitions in 2019 by each quarter.
Q1 M&A Activity
Johnson & Johnson Acquires Auris Health for $3.4B to Expand Digital Surgery Portfolio
Johnson & Johnson acquiresAuris Health, a developer of robotic technologies for $3.4 billion in cash. Auris Health is a privately-held developer of
Read More
CareDx Acquires OTTR for $16M to Enable EMR Integrations at Transplant Centers
CareDx, Inc., a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients has agreed to acquire OTTR Complete Transplant Management (“OTTR”), a provider of organ transplant patient tracking software.Financial DetailsCareDx will pay approximately $16M to acquire OTTR and intends to fund the transaction with cash on hand. For the full year 2019, OTTR’s revenue is projected to be
Read More
Octave Bioscience Grabs $14M for Care Management Platform Focused on Neurodegenerative Diseases
Octave Bioscience lands $14M to bring expertise in chronic neurodegenerative markets and molecular Insights for improved care.Octave Bioscience, a Menlo Park, CA-based developer of a fully integrated care management platform delivering powerful insights for patients with neurodegenerative diseases, today announced it has raised $14 million in Series A funding. The round was led by BCBS Venture Partners with participation from Echo Health Ventures (a strategic collaboration of Cambia Health
Read More
University of Michigan, Tempus Partner on Personalized Breast Cancer Medicine Initiative
Breast cancer is the most common non-skin cancer and the second leading cause of cancer-related death in women. In 2017, it is estimated that more than 250,000 U.S. women will be diagnosed with new cases of invasive breast cancer. That’s why the University of Michigan Comprehensive Cancer Center has partnered with Tempus on a personalized cancer medicine initiative aimed providing most effective care for individuals diagnosed with breast cancer.As part of the initiative, Tempus will use
Read More
Penn Medicine’s Abramson Cancer Center Launches Initiative to Improve & Personalize BRCA Mutations
Cancer experts at the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania have announced a new collaboration with Tempus to improve and personalize treatment for patients with heritable BRCA mutations. Tempus, a technology company focused on helping doctors personalize cancer treatment will analyze the molecular and clinical data of patients who were treated at the Basser Center and harbor a BRCA mutation using machine learning and advanced
Read More
Precision Medicine Startup AltheaDx Lands $27M to Expand Personalized Therapeutic Decisions Internationally
AltheaDx, Inc., a San Diego, CA-based commercial stage molecular diagnostics company specializing in the field of personalized medicine has raised $27 million in Series D funding. The company is a CAP-accredited, CLIA-certified laboratory and plans to utilize the funding to expands its sales force and marketing efforts to grow internationally.IDgenetix, the company’s product testing portfolio, enables personalized therapeutic decisions for patients suffering from some of the most prevalent
Read More
